In June 2022 we reported that favourable results from a trial of a new cancer drug, Enhertu (trastuzumab deruxtecan), had been presented at this year’s meeting of the American Society of Clinical Oncology and had
Dr Coffelt and his team at the Beatson Institute for Cancer Research in Glasgow in another project funded by Secondary1st’s fundraisers and donors are working to understand why existing immunotherapies are less effective in treating
At the University of Bradford in one of the projects funded by the wonderful donors and fundraisers of Secondary1st Professor Pors and his PhD student Enrica are continuing their work to improve duocarmycins, a very
Staff and students from Francis Holland School Regent’s Park put on fancy dress and took part in a sponsored walk around Regent’s Park to raise money for Secondary1st. The weather was ideal to enjoy an
In recently published draft guidance NICE has approved the routine use of another drug combination for some people with secondary breast cancer. Palbociclib, also known as Ibrance, is a targeted drug made by Pfizer and
Ruth and Stu are preparing to fly to Nepal where they will take part in a 22-day expedition to the summit of Imja Tse, the Nepalese name of Island Peak. Imja Tse is 6200 metres
Paul will be running the London Marathon on 2nd October to raise money for Secondary1st in memory of his sister-in-law Poppy. He has been training hard through the summer heat and completed an 18-mile run
Catherine did it and more! She walked the length of Hadrian’s Wall and then walked on for another seventeen miles to raise money for Secondary1st. She crossed the country from Wallsend near Newcastle to Bowness-on-Solway
Catherine has spent weeks and weeks preparing for August 2nd when she will set off to walk the 100km length of Hadrian’s Wall east to west across the north of England from Wallsend to Bowness-on-Solway.
Final draft guidance from NICE now recommends that two drugs to treat two different types of secondary or metastatic breast cancer be made available through the Cancer Drugs Fund. Piqray or alpelisib is a kinase